Alpine Immune Sciences Stock Net Asset
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Alpine Immune Sciences fundamentals help investors to digest information that contributes to Alpine Immune's financial success or failures. It also enables traders to predict the movement of Alpine Stock. The fundamental analysis module provides a way to measure Alpine Immune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alpine Immune stock.
Alpine |
Alpine Immune Sciences Company Net Asset Analysis
Alpine Immune's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Alpine Immune Net Asset | 381.81 M |
Most of Alpine Immune's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alpine Immune Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Alpine Immune Sciences has a Net Asset of 381.81 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Alpine Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alpine Immune's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alpine Immune could also be used in its relative valuation, which is a method of valuing Alpine Immune by comparing valuation metrics of similar companies.Alpine Immune is currently under evaluation in net asset category among its peers.
Alpine Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X | |||
| Price To Book | 12.87 X | |||
| Price To Sales | 71.68 X | |||
| Revenue | 58.88 M | |||
| Gross Profit | (40.18 M) | |||
| EBITDA | (43.67 M) | |||
| Net Income | (32.18 M) | |||
| Cash And Equivalents | 167.86 M | |||
| Cash Per Share | 5.52 X | |||
| Total Debt | 9.91 M | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 2.75 X | |||
| Book Value Per Share | 5.08 X | |||
| Cash Flow From Operations | (79.01 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (0.64) X | |||
| Target Price | 62.0 | |||
| Number Of Employees | 142 | |||
| Beta | 0.97 | |||
| Market Capitalization | 4.46 B | |||
| Total Asset | 381.81 M | |||
| Retained Earnings | (256.14 M) | |||
| Working Capital | 288.05 M | |||
| Current Asset | 25.53 M | |||
| Current Liabilities | 3.39 M | |||
| Net Asset | 381.81 M |
About Alpine Immune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alpine Immune Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alpine Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alpine Immune Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |